Benda Kithaka
Research Subjects
Research Interests
Benda Kithaka has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Belmira Rodrigues
African Organisation for Research and Training in Cancer, Cape Town, South Africa
2 shared publications- C. S. Pramesh
Thoracic Surgery (Surgical Oncology), Tata Memorial Centre, National Cancer Grid, and Homi Bhabha National Institute, Mumbai, India
2 shared publications - Edith Grynszpancholc
Fundación Natalí Dafne Flexer, Buenos Aires, Argentina
2 shared publications - Eduardo Cazap
Sociedad Latino Americana y del Caribe De Oncología Médica, RINC-SLACOM, Buenos Aires, Argentina
2 shared publications - Laura Esfeller
SWOG Cancer Research Group, San Bernardino, CA
2 shared publications - Linsey Eldridge
Center for Global Health, National Cancer Institute, National Institutes of Health, Rockville, Maryland
2 shared publications
Latest Publications
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (Supplement) , 1-3
14th Annual Symposium on Global Cancer Research: From Local Discovery to Global Impact
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (Supplement) , 1-3
14th Annual Symposium on Global Cancer Research: From Local Discovery to Global Impact
- 1 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (12_Supplem) , e1-e2
13th Annual Symposium on Global Cancer Research: Reflections on Growth, Adaptation, and Commitment to Global Cancer Control
We are pleased to present the accepted abstracts from the 13th Annual Symposium on Global Cancer Research (ASGCR). The 2025 symposium highlights both the commitment and growth of the global oncology community, marking 5 years since ASGCR’s transition to a fully virtual format. What began as a pandemic-driven necessity has evolved into a deliberate strategy to broaden participation and minimize barriers. Over this period, ASGCR has expanded its reach, expanded its content, and strengthened global collaboration through initiatives such as requiring low- and middle-income country coauthorship, launching the Early Career Investigator Day, and adopting open calls for scientific session proposals.
- 1 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (12_Supplem) , e1-e2
13th Annual Symposium on Global Cancer Research: Reflections on Growth, Adaptation, and Commitment to Global Cancer Control
We are pleased to present the accepted abstracts from the 13th Annual Symposium on Global Cancer Research (ASGCR). The 2025 symposium highlights both the commitment and growth of the global oncology community, marking 5 years since ASGCR’s transition to a fully virtual format. What began as a pandemic-driven necessity has evolved into a deliberate strategy to broaden participation and minimize barriers. Over this period, ASGCR has expanded its reach, expanded its content, and strengthened global collaboration through initiatives such as requiring low- and middle-income country coauthorship, launching the Early Career Investigator Day, and adopting open calls for scientific session proposals.
- Open Access
- 1 September 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2300285
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource–Stratified Guideline
PURPOSE: To guide clinicians and policymakers in three global resource-constrained settings on treating patients with metastatic breast cancer (MBC) when Maximal setting–guideline recommended treatment is unavailable. METHODS: A multidisciplinary, multinational panel reviewed existing ASCO guidelines and conducted modified ADAPTE and formal consensus processes. RESULTS: Four published resource-agnostic guidelines were adapted for resource-constrained settings; informing two rounds of formal consensus; recommendations received ≥75% agreement. RECOMMENDATIONS: Clinicians should recommend treatment according to menopausal status, pathological and biomarker features when quality results are available. In first-line, for hormone receptor (HR)–positive MBC, when a non-steroidal aromatase inhibitor and CDK 4/6 inhibitor combination is unavailable, use hormonal therapy alone. For life-threatening disease, use single-agent chemotherapy or surgery for local control. For premenopausal patients, use ovarian suppression or ablation plus hormone therapy in Basic settings. For human epidermal growth factor receptor 2 (HER2)–positive MBC, if trastuzumab, pertuzumab, and chemotherapy are unavailable, use trastuzumab and chemotherapy; if unavailable, use chemotherapy. For HER2-positive, HR-positive MBC, use standard first-line therapy, or endocrine therapy if contraindications. For triple-negative MBC with unknown PD-L1 status, or if PD-L1–positive and immunotherapy unavailable, use single-agent chemotherapy. For germline BRCA1/ 2 mutation–positive MBC, if poly(ADP-ribose) polymerase inhibitor is unavailable, use hormonal therapy (HR-positive MBC) and chemotherapy (HR-negative MBC). In second-line, for HR-positive MBC, Enhanced setting recommendations depend on prior treatment; for Limited, use tamoxifen or chemotherapy. For HER2-positive MBC, if trastuzumab deruxtecan is unavailable, use trastuzumab emtansine; if unavailable, capecitabine and lapatinib; if unavailable, trastuzumab and/or chemotherapy (hormonal therapy alone for HR-positive MBC). Additional information is available at www.asco.org/resource-stratified-guidelines . It is ASCO's view that healthcare providers and system decision-makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.
- 1 September 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2300285
Open AccessSystemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource–Stratified Guideline
PURPOSE: To guide clinicians and policymakers in three global resource-constrained settings on treating patients with metastatic breast cancer (MBC) when Maximal setting–guideline recommended treatment is unavailable. METHODS: A multidisciplinary, multinational panel reviewed existing ASCO guidelines and conducted modified ADAPTE and formal consensus processes. RESULTS: Four published resource-agnostic guidelines were adapted for resource-constrained settings; informing two rounds of formal consensus; recommendations received ≥75% agreement. RECOMMENDATIONS: Clinicians should recommend treatment according to menopausal status, pathological and biomarker features when quality results are available. In first-line, for hormone receptor (HR)–positive MBC, when a non-steroidal aromatase inhibitor and CDK 4/6 inhibitor combination is unavailable, use hormonal therapy alone. For life-threatening disease, use single-agent chemotherapy or surgery for local control. For premenopausal patients, use ovarian suppression or ablation plus hormone therapy in Basic settings. For human epidermal growth factor receptor 2 (HER2)–positive MBC, if trastuzumab, pertuzumab, and chemotherapy are unavailable, use trastuzumab and chemotherapy; if unavailable, use chemotherapy. For HER2-positive, HR-positive MBC, use standard first-line therapy, or endocrine therapy if contraindications. For triple-negative MBC with unknown PD-L1 status, or if PD-L1–positive and immunotherapy unavailable, use single-agent chemotherapy. For germline BRCA1/ 2 mutation–positive MBC, if poly(ADP-ribose) polymerase inhibitor is unavailable, use hormonal therapy (HR-positive MBC) and chemotherapy (HR-negative MBC). In second-line, for HR-positive MBC, Enhanced setting recommendations depend on prior treatment; for Limited, use tamoxifen or chemotherapy. For HER2-positive MBC, if trastuzumab deruxtecan is unavailable, use trastuzumab emtansine; if unavailable, capecitabine and lapatinib; if unavailable, trastuzumab and/or chemotherapy (hormonal therapy alone for HR-positive MBC). Additional information is available at www.asco.org/resource-stratified-guidelines . It is ASCO's view that healthcare providers and system decision-makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.
- 1 November 2021
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 76 (11) , 675-677
National Action Towards a World Free of Cervical Cancer for All Women
(Abstracted from Prev Med 2021;144:106313) Cervical cancer is a preventable disease that continues to have an annual incidence of nearly 600,000 cases with disproportionate disease burden and death occurring in marginalized populations and low- and middle-income countries. Evidence suggests that elimination of cervical cancer as a public health problem is more feasible than it has ever been, and that the incidence can be brought below 4 per 100,000 women globally within a century.
- 1 November 2021
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 76 (11) , 675-677
National Action Towards a World Free of Cervical Cancer for All Women
(Abstracted from Prev Med 2021;144:106313) Cervical cancer is a preventable disease that continues to have an annual incidence of nearly 600,000 cases with disproportionate disease burden and death occurring in marginalized populations and low- and middle-income countries. Evidence suggests that elimination of cervical cancer as a public health problem is more feasible than it has ever been, and that the incidence can be brought below 4 per 100,000 women globally within a century.